Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma

Gastrointestinal Cancer Research

Volumn 4, Issue 3, 2011, Pages 78-83

  Sanoff, Hanna K ^a,b   Bernard, Stephen ^a,b   Goldberg, Richard M ^a,b   Morse, Michael A ^c   Garcia, Reynaldo ^b   Woods, Lynna ^b   Moore, Dominic T ^b   O'Neil, Bert H ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CAPECITABINE; CETUXIMAB; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RADIOFREQUENCY ABLATION; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 80053012405     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ries L, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007
2. International Agency for Cancer Research: Available at: http://www-dep.iarc.fr/
3. Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/ interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538, 2005
4. Lai CL, Wu PC, Chan GC et al: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 62:479-483, 1988
5. Llovet J, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 359:378-390, 2008
6. Ito Y, Takeda T, Sakon M, et al: Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 84:1377-1383, 2001
7. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663, 2005
8. Mendelsohn J, Baird A, Fan Z, et al: Growth factors and their receptors in epithelial malignancies, in Mendelsohn J, Howley PM, Israel M, Liotta L (eds): The Molecular Basis of Cancer. Philadelphia, PA, W. B. Saunders Company, pp 137-144, 2001
9. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17:259-269, 1999
10. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
11. Yen Y, Doroshow J, Leong D, et al: Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer. J Clin Oncol 22(14S), 2004 (abstr 4169)
12. Synold TW, Takimoto CH, Doroshow JH, et al: Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13:3660-3666, 2007
13. Boige V, Raoul JL, Pignon JP, et al: Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 97:862-867, 2007
14. Sun W, Haller D, Mykulowycz K, et al: Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol 25(18S), 2007 (abstr 4574)
15. Zhu AX, Stuart K, Blaszkowsky LS, et al: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:581-589, 2007
16. Gruenwald V, Wilkens L, Gebel M, et al: A phase II open label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol 25(18S), 2007 (abstr 4598)
17. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 360:1408-1417, 2009
18. Wong CM, Ng IO: Molecular pathogenesis of hepatocellular carcinoma. Liver Int 28:160-174, 2008
19. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
20. Berasain C, Garcia-Trevijano ER, Castillo J, et al: Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology 128:424-432, 2005
21. Asnacios A, Fartoux L, Romano O, et al: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 112:2733-2739, 2008
22. O'Neil BH, Allen R, Spigel DR, et al: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25:3644-3648, 2007